Pharma Sector

'India pharma resilient despite disruptions; no blanket price hike planned'

India's pharma sector remains resilient despite West Asia disruptions, as the government advances biopharma, R&D and bulk drug manufacturing initiatives

Scheme to build bulk drugs' R&D, capacity in works, says Pharma secy

India plans a new support scheme for bulk drugs focused on R&D and capacity creation, while ruling out a broad medicine price hike despite rising input costs

Uttar Pradesh govt plans to develop pharma ecosystem over 8,000 acres

Uttar Pradesh plans an 8,000-acre healthcare manufacturing ecosystem to attract investments, boost exports and emerge as a major pharma hub

MSME drugmakers face capital stress amid prolonged West Asia disruptions

Cost pressures, inventory strains likely to hit margins by 3-5%

Govt approves Skymap Pharma's ₹121 crore bid for IMPCL stake sale

The Centre approved Skymap Pharmaceuticals' Rs 121 crore bid for the strategic sale of its stake in Indian Medicines Pharmaceutical Corporation Ltd

Anupam Rasayan to acquire up to 43% stake in Bliss GVS Pharma for ₹1,369 cr

Specialty chemicals maker Anupam Rasayan India has signed an agreement to acquire up to 43.3 per cent stake in pharmaceutical formulations company Bliss GVS Pharma Ltd for an estimated Rs 1,369.51 crore and launch an open offer to acquire a further 26 per cent in the firm, according to a statement The Surat-based company will acquire a 43.3 per cent stake at Rs 299 per share for Rs 1,369.51 crore, and launch a mandatory open offer for an additional 26 per cent from public shareholders at the same price, Anupam Rasayan said in a late-night regulatory filing. "We have entered into a definitive agreement to acquire 43.3-48.2 per cent equity stake and are making an open offer to the public shareholders of Bliss GVS Pharma," Anupam Rasayan India Managing Director Anand Desai said. The acquisition will be funded through a Rs 300 crore term loan, with the remaining amount financed via a non-controlling, non-voting equity instrument. "This will strategically strengthen our presence across

High-value clinical research marks gradual shift to India: Parexel

Parexel says India is evolving into a strategic innovation and clinical research hub as global pharmaceutical firms shift high-value functions and decision-making roles

Datanomics: Digital vs traditional in the race for e-pharmacy growth

Traditional pharmacists protest as online pharmacy firms dominate India's drug retail market, outpacing brick-and-mortar players in growth and funding

Torrent Pharma Q4 profit falls 21.9% on high expenses despite revenue boost

Torrent Pharma's Q4 profit dropped 22% as JB Pharma integration costs pushed up expenses, despite strong growth in semaglutide-led revenues

Why pharma stocks are emerging as safe bet amid global market turmoil

The pharma sector is seen as a safe bet because demand remains steady even during inflation or economic slowdowns. Besides, companies earn revenue from multiple global markets, which helps reduce risk

Mankind Pharma Q4 PAT rises 30% on strong domestic biz, chronic push

Mankind Pharma posted a 30.4% rise in Q4FY26 profit, driven by strong demand for chronic therapies and OTC healthcare products

Alembic Pharma shares plunge 9% on soft Q4 results, weak margins drag

Alembic Pharmaceuticals reported a 29 per cent year-on-year (Y-o-Y) rise in consolidated net profit to ₹202 crore as compared to ₹157 crore in the year-ago period

Biosimilars could surpass generics in US mkt by early 2030s: Dr Reddy's CEO

Dr Reddy's CEO Erez Israeli says semaglutide, biosimilars and oncology will drive the company's next growth phase as it expands beyond traditional generics globally

Zydus to acquire Assertio in ₹1,570 crore deal to expand US business

Acquisition gives Zydus a branded-drugs commercial platform in the US and strengthens its specialty pharmaceutical presence in pain and oncology therapies

Cipla Q4 profit plunges 55% to ₹554.6 cr amid US drag, higher R&D spend

Drugmaker cites lower contribution from key US products, higher R&D investments and rising operating costs as Q4 FY26 profit declines sharply

Cipla shares jump 5% after Q4 results; records highest-ever yearly revenue

Cipla reported total income from operations of ₹6,541 crore, down 2.8 per cent year-on-year (Y-o-Y) from ₹6,730 crore in the year-ago period

India's next pharma leap will be built on smarter global regulations

A risk-based system allows regulators to pay attention where it matters most, while providing industry with predictability

Pharma, healthcare funds are in recovery mode. Should you enter them now?

Hold existing investments if you have a long horizon; book partial profits if exposure exceeds 10 per cent

Dr Reddy's Q4 PAT crashes 86% on generic Revlimid shock in US market

The fall was driven by weak US sales of Revlimid, offset only partially by growth in India, Europe, and emerging markets

Cipla Q4 preview: Profit may plunge on weak US sales; check estimates here

Cipla's March 2026 quarter revenue is expected to decline marginally to ₹6,665 crore as compared to ₹6,730 crore in the year-ago period